Momenta Phama (MNTA) Misses Q3 EPS by 8c, Revenues Miss

Momenta Phama (NASDAQ: MNTA) reported Q3 EPS of ($0.65), $0.08 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $14.88 million versus the consensus estimate of $16.99 million.

“We recently highlighted our pipeline of novel drug candidates for immune-mediated disorders at our recent R&D Day and, as we look to early 2019, we plan to have two Phase 2 trials of M281 initiated in gMG and HDFN and one Phase 1/2 trial of M254 initiated in ITP,” said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. “To complement the advancement of our novel drug pipeline, we have ongoing revenues from our Glatopa franchise as well as two late-stage biosimilar assets which have the potential to be important revenue drivers to support our novel drug pipeline. We recently executed agreements with AbbVie enabling the global launch of M923, our proposed biosimilar to HUMIRA®, in the European Union and in the United States in November 2023, subject to regulatory approval. Additionally, our research platform is showing broad applicability and we believe it will generate additional pipeline expansion opportunities.”

For earnings history and earnings-related data on Momenta Phama (MNTA) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Dawson Geophysical (DWSN) Reports Q2 Loss of $0.11
• Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance